Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Citi
Chubb
Johnson and Johnson
Daiichi Sankyo
Covington
McKinsey
Merck
Argus Health

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,753,646

« Back to Dashboard

Which drugs does patent 5,753,646 protect, and when does it expire?

Patent 5,753,646 protects APTIOM and is included in one NDA.

This patent has twenty-five patent family members in twenty countries.
Summary for Patent: 5,753,646
Title: Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them
Abstract:New compounds of general formula I, including all possible stereoisomers, are described ##STR1## wherein: R is hydrogen, alkyl, aminoalkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenyl or substituted phenyl or pyridyl group. A process for their preparation consists of reaction of compound II ##STR2## with an acylating agent.
Inventor(s): Benes; Jan (Oporto, PT), Soares Da Silva; Patricio M. V. A. (Oporto, PT)
Assignee: Portela & Ca., S.A. (Oporto, PT)
Application Number:08/673,819
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,753,646
Patent Claim Types:
see list of patent claims
Compound; Process; Use; Composition;

Drugs Protected by US Patent 5,753,646

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-001 Nov 8, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF PARTIAL-ONSET SEIZURES ➤ Sign Up
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-002 Nov 8, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF PARTIAL-ONSET SEIZURES ➤ Sign Up
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-003 Nov 8, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF PARTIAL-ONSET SEIZURES ➤ Sign Up
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-004 Nov 8, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF PARTIAL-ONSET SEIZURES ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,753,646

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Portugal101732Jun 30, 1995

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
QuintilesIMS
Mallinckrodt
Daiichi Sankyo
Chubb
Argus Health
AstraZeneca
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.